Table 4:
Associations of cancer with DCGF, DWFG, and the combined outcomes across calendar periods, by cancer diagnosis date lymphoma
| DCGF HR (95%C) | P-value | DWFG HR (95%CI) | P-value | Combined Outcomes HR (95%CI) | P-value | |
|---|---|---|---|---|---|---|
| All Cancer | 0.346 | 0.257 | 0.258 | |||
| 1987–1996 | 1.97 (1.51, 2.55) | 10.64 (9.19, 12.33) | 5.38 (4.76, 6.10) | |||
| 1997–2006 | 1.85 (1.04, 3.27) | 9.74 (7.12, 13.33) | 5.55 (4.25, 7.24) | |||
| 2007–2016 | 2.30 (1.24, 4.27) | 10.97 (7.78, 15.47) | 6.12 (4.57, 8.19) | |||
| NHL | 0.048 | 0.007 | 0.002 | |||
| 1987–1996 | 6.32 (3.86, 10.34) | 19.71 (14.01, 27.74) | 11.68 (8.84, 15.45) | |||
| 1997–2006 | 3.45 (1.15, 10.36) | 9.78 (4.57, 20.95) | 6.10 (3.27, 11.38) | |||
| 007–2016 | 2.31 (0.60, 8.85) | 11.72 (5.22, 26.30) | 7.14 (3.61, 14.10) | |||
| Non-NHL Cancer | 0.080 | 0.570 | 0.068 | |||
| 1987–1996 | 1.54 (1.14, 2.10) | 9.30 (7.94, 10.90) | 4.69 (4.09, 5.38) | |||
| 1997–2006 | 1.63 (0.84, 3.16) | 9.33 (6.66, 13.06) | 5.36 (4.00, 7.17) | |||
| 2007–2016 | 2.29 (1.13, 4.62) | 10.17 (7.03, 14.71) | 5.80 (4.22, 7.98) |
Abbreviations: DCGF death-censored graft failure, DWFG death with functioning graft, NHL non-Hodgkin lymphoma
Hazard ratio estimates (95% CIs) compare KTRs with cancer to those without cancer and are adjusted for age, gender, race/ethnicity (white, black, Hispanic, Asian), body mass index, kidney donor status (living vs. deceased), waiting time for transplant, cause of ESKD, and induction and maintenance immunosuppression medications.
P-values are for tests of interaction of cancer by calendar period, and bold text indicates interactions that are statistically significant (p < 0.05).